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The genomic region at 9p21 chromosome near the CDKN2A/CDKN2B genes is associated with type 2 diabetes(T2D)
and cardiovascular disease(CVD). The effect of the 9p21 locus on long-term mortality in patients with T2D has yet
to be determined.
We examined three single nucleotide polymorphisms (SNPs) on 9p21, consistently and independently associated
with T2D (rs10811661) or CVD (rs10757278, rs2383206), in relation to the risk of total and cardiovascular mortality in
diabetic patients. We also aimed to replicate the previously observed interaction between rs2383206 and glycemic
control on mortality.
Genotypes for three SNPs were determined in 914 individuals from a prospective cohort of T2D patients of Dutch
origin. Associations with mortality were assessed using Cox proportional hazard analyses.
After a median follow-up of 9.5 years, 358 out of 914 patients had died. The hazard ratio (HR) for total mortality
among individuals homozygous for the T2D-risk allele of rs10811661 compared to non-homozygous individuals was
0.74(95%CI 0.59-0.93). For the carriers of both CVD-risk alleles of rs10757278, the HR for total mortality was 1.31(95%
CI 1.01-1.70). We found a significant interaction between rs2383206 and HbA1c on mortality, which was higher
among patients with two CVD-risk alleles in the two lowest HbA1c tertiles (HR 1.68(95%CI 1.08-2.63); HR 1.48(95%CI
1.01-2.18).
In conclusion, common variants on 9p21 were associated with mortality in patients with T2D in a Dutch
population. The T2D SNP was inversely associated with mortality, while the CVD SNP increased the risk for mortality.
We confirmed a possible, although different, synergistic relationship between HbA1c and rs2383206 on total mortality.
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Patients with type 2 diabetes (T2D) have a high risk for
cardiovascular morbidity and mortality [1]. Multiple risk
factors contribute to their development, including ge-
netic factors [2-5]. Genome-wide association (GWA)
studies for T2D [2-4] and cardiovascular disease (CVD)
have identified the same susceptibility locus on chromo-
some 9p21 [5,6]. In this genomic region near the
protein-coding genes CDKN2A and CDKN2B containing* Correspondence: g.w.d.landman@isala.nl
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reproduction in any medium, provided the ortwo adjacent linkage disequilibrium (LD) blocks the
two single nucleotide polymorphisms (SNPs), rs10811661
and rs10757278, were consistently replicated as having
an independent association with T2D and CVD,
respectively [5,7,8].
Several studies indicated that the 9p21 locus might
represent a genetic modulator in the cardiovascular sys-
tem. Different pathophysiological pathways have been
proposed, including the initiation and possibly progres-
sion of coronary atherosclerosis and development of
multivessel coronary artery disease (CAD) [9-11]. One
of these studies showed an effect of the 9p21 region on
progression of plaques in the presence of already estab-
lished CVD among non-diabetics, although this effectral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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modulation of effect of common 9p21 variants on CVD
risk by degree of glycemic control has been reported
[12]. Doria et al. reported an increased risk of CAD and
mortality in the presence of poor glycemic control in
T2D patients and also suggested a synergism between
the high ‘CVD’-risk genotype of rs2383206 and poor
glycemic control on mortality [12]. Whether the poly-
morphisms on 9p21 can predict overall or cardiovascular
mortality in patients with T2D and how this asso-
ciation is modulated by glycemic control is still to be
determined.
In this study we aimed to investigate the total and car-
diovascular mortality risk in association with the
‘T2D‘SNP rs10811661 and the ‘CVD’ SNP rs10757278 in
a prospective cohort study of type 2 diabetes patients of
Dutch origin. Next, we aimed to replicate the findings
obtained by Doria et al. on the interaction between the
rs2383206 variant and level of glycemic control and its
effects on total and CVD mortality.Methods
Study population
In 1998, a large shared-care diabetes project was
initiated: the Zwolle Outpatient Diabetes project Inte-
grating Available Care (ZODIAC) [10]. Of all the patients
that were invited, 90% participated in this study and 10%
were excluded or refused to participate. Type 2 diabetes
was defined according to the World Health Organization
(WHO) criteria (random plasma glucose level >11.1
mmol/l or a fasting plasma glucose level >7.0 mmol/l)
[13]. Patients with a very short life expectancy, with in-
sufficient cognitive abilities and those treated by an in-
ternist were excluded. At the end of the project’s first
year (1998) and the start of the second year (1999), blood
was taken and stored for future research and quality con-
trol. The majority of the participants were of Dutch Cau-
casian origin [11]. Baseline data involved recording a full
medical history including the presence of any macrovas-
cular complications, medication use and tobacco expo-
sure. Patients were considered having macrovascular
complications if they had a history of angina pectoris,
myocardial infarction, percutaneous transluminal coro-
nary angioplasty, coronary artery bypass grafting, stroke
or transient ischemic attack. Laboratory and physical as-
sessment data were collected and included glycated
hemoglobin (HbA1c), nonfasting lipid profile, serum
creatinine (SCr, a kinetic colorimetric Jaffé method
[Modular P Analyzer; Roche, Almere, the Netherlands]
was used), albumin-to-creatinine ratio (ACR) using immu-
nonephelometry (Behring Nephelometer; Behringwerke,
Mannheim, Germany), blood pressure (measured twice
with a Welch Allyn sphygmomanometer in the supineposition after at least 5 min of rest). Height and weight
were measured while the participants were dressed in light
clothing and without shoes. HbA1c was measured by
affinity-based high-performance liquid chromatography
on a primus CLC 385 (Primus Diagnostics, Kansas city,
Missouri, USA) by the Isala Clinics Laboratory.
Life status and cause of death were retrieved in 2009
from records maintained by the hospital and the GPs.
Causes of death were coded according to The Inter-
national Classification of Diseases, 9th Revision (ICD-9).
DNA samples were available for 914 T2D patients. The
ZODIAC study and the informed consent procedure
were approved by the local medical ethics committee.
Informed consent was obtained from all patients.
Genotyping
Based on the original GWA scan by Helgadottir et al.
[8], we selected the SNPs rs10811661 and rs10757278
on the 9p21 locus reported to be strongly associated and
consistently replicated with T2D and CVD, respectively,
in European populations [5,6,8]. These variants and the
SNP rs2383206 (LD with rs10757278 r2=0.86 (HapMap
phase III, release 2)) from the study by Doria et al. [12]
were genotyped using TaqMan assays (Applied Biosys-
tems, Nieuwekerk a/d IJssel, The Netherlands). Assays
were performed according to the manufacturer’s specifi-
cations and the genotypes were analyzed using a Taq-
Man 7900HT (Applied Biosystems). The DNA samples
were processed in 384-well plates and each plate con-
tained 16 genotyping controls (4 duplicates of 4 different
Centre d’Etude du Polymorphisme Humain (CEPH)
samples). There were no discordances in the genotypes
of any of the CEPH samples or the CEU data available
from HapMap. The genotype success rates were 97.8%,
96.6% and 98.5% for rs10811661, rs10757278 and
rs2383206, respectively. Figure 1 shows the LD plot
among the three genotyped SNPs of our study.
Statistical analysis
Univariate analysis was performed to test the relationships
between the genotypes and baseline variables (i.e. age,
gender, diabetes duration, history of macrovascular com-
plications, smoking status, body mass index (BMI), Hba1c
(%), systolic blood pressure, serum creatinine, total
cholesterol-HDL ratio, and urinary albumin-to-creatinine
ratio) using a student’s t-test for normally distributed
data and a Mann Whitney U test for non-normally dis-
tributed data. Associations of the SNPs with macrovas-
cular disease and other metabolic factors at baseline
were assessed with univariate and by multivariate logistic
regression analysis. In this model, adjustment was made
for 11 variables.
A Cox proportional hazard model was constructed to
assess the association between the SNPs rs10811661 and
Figure 1 Pairwise linkage disequilibrium (LD) plot, calculated as r2, among genotyped SNPs. Red and white colours indicate high and low
level of LD, respectively. The r2 measures of LD are shown in the squares.
Table 1 Baseline characteristics of the study population
Characteristics Total number of patients
N=914
Age (in years) 67.9 (±11.3)
Sex (% women) 57.8
Diabetes duration (in years) 5.0 (2–10)
Smoking (%) 18.1
Macrovascular complications (%) 31.1
BMI (kg/m2) 28.9 (±4.6)
HbA1c (%) 7.3 (±1.1)
Systolic blood pressure (mmHg) 152.5 (±25.1)
eGFR (ml/min/1,73 m2) 74.3 (±27.1)
Total cholesterol-HDL ratio 5.0 (±1.4)
Albumin creatinine ratio 1.9 (1.0-5.9)
Data are means ±SD or median with interquartile range for non-normally
distributed data or %.
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vascular mortality after follow-up. SNPs were coded by
genotype as 0,1, and 2 with individuals homozygous for
the non-risk allele as the reference group. The risk and
non-risk alleles were defined on the basis of the results
from the discovery GWAS studies [2,4,6]. The recessive
genetic model was selected prior to the analysis in con-
junction with all previous prospective studies [12,14-17],
i.e. the carriers of two copies of the risk allele (genotype
2) were compared versus the heterozygotes or non-
carriers of the risk allele (genotypes 1 or 0).
We used two different models. In model 1, adjustment
for age and gender was included, while model 2 included
nine additional baseline variables as mentioned above
and also in Table 1. All variables, except gender, smoking
status and macrovascular complications were added as
continuous variables.
For the replication analysis of the rs2383206 by HbA1c
interaction, we constructed a Cox proportional hazard
model with the primary endpoint of total and cardiovas-
cular mortality. In conjunction with the study by Doria
[12], the presence of interaction was tested by adding a
cross-product term to the Cox proportional hazard
model including glycemic control and rs2383206 geno-
type using the same genetic model as in study by Doria
et al., i.e. the recessive model [12], together with age at
baseline and sex as main effects. If interaction could be
confirmed, we then repeated the multivariate analysis
stratified according to the HbA1c subgroups. In concur-
rence with the aforementioned study, HbA1c was cate-
gorized in tertiles [12].For cardiovascular mortality, all competing deaths
were treated as censored observations at time of death.
Patients without a known cause of death were censored
in this analysis. Continuous variables were centered to
avoid co-linearity. The proportional hazards assumption
was examined using log (−log) survival plots. The pro-
portional hazard assumptions were met for all analyses.
All analyses were performed with SPSS version 15.0.1
(SPSS inc., Chicago, Illinois, USA), and a two-sided
p-value of <0.05 was considered statistically significant.
Figure 2 Total mortality in type 2 diabetes patients in relation
to the rs10811661 genotypes. Survival curves indicate a lower risk
for total mortality in carriers of both risk alleles of the ‘T2D’ variant
rs10811661 compared to patients either homozygous or
heterozygote for the non-risk allele. The HR was adjusted for
multiple baseline covariates (model 2).
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The baseline characteristics of the study population are
presented in Table 1. The average age was 68 years with
a median diabetes duration of 5 years, 31% had macro-
vascular complications at baseline and the average
HbA1c was 7.3%. During a median follow-up period of
9.5 years, 358 (39%) patients had died. Cause of death
was known for 336 (94%) patients. The proportion of
deaths attributable to cardiovascular diseases was 41%
(n=146).
In the univariate analysis, all the baseline characteris-
tics - age, gender, duration of diabetes, smoking status,
macrovascular complications at baseline, BMI, HbA1c,
systolic blood pressure, serum creatinine, total choles-
terol to HDL-cholesterol ratio, and albuminuria creati-
nine ratio – were not significantly different between the
groups according to the rs10811661, rs10757278 or
rs2383206 genotypes. Also, insulin use was not different
according to the different genotypes.
In the multivariate analysis, patients with the ‘CVD’-
risk genotype of rs107577278 had an increased risk for
macrovascular complications at baseline compared to
the non-carriers (OR 1.65 (95% CI 1.08-2.36, p=0.02)).
There were no associations between the genotypes for
rs10811661 and rs2383206 and macrovascular disease at
baseline. All other baseline variables in the cross-
sectional analysis were not associated with the T2D and
CVD risk alleles.
The ‘T2D’ risk variant rs10811661 and mortality
In our study, the hazard ratio (HR) for total mortality in
the patients carrying both ‘T2D’- risk alleles (the TT-
genotype) was 0.79 (95%CI 0.63-0.99, p=0.04) for model
1 and 0.74 (95%CI 0.59-0.93, p=0.01) for model 2 com-
pared to carriers of the non-risk allele (the CT and CC
genotypes), see Table 2 and Figure 2. Although the effect
size was similar with a HR of 0.76, there was no signifi-
cant relationship between rs10811661 and cardiovascular
mortality (Table 2).Table 2 Cox proportional hazard analyses for total and cardio
according to the rs10811661 and rs10757278 genotypes afte
Genotype N of patients (deceased) HR total mortalitya
rs10811661
CT/CC 264 (113) 1
TT 635 (238) 0.79 (0.63 -0.99)
Missing 15 (7) p=0.04
rs10757278
AA/AG 704 (266) 1
GG 188 (81) 1.33 (1.04-1.71)
Missing 22 (11) p =0.02
a Corrected for age and sex according to model 1, b corrected for 11 baseline variab
smoking status, BMI, Hba1c, systolic blood pressure, serum creatinine, total cholesteThe ‘CVD’ risk variant rs10757278 and mortality
The risk of total mortality was higher in individuals carry-
ing both risk alleles of rs10757278 (the GG-genotype) as
compared with patients heterozygous or homozygous for
the non-risk allele (the AA and AG genotypes). For model
1 the HR was 1.33 (95%CI 1.04-1.71, p=0.02) (Table 2).
For the fully adjusted model 2 the HR was 1.31 (95%CI
1.01-1.70, p=0.03). We found no significant association be-
tween rs10757278 and cardiovascular mortality (Table 2).vascular mortality among type 2 diabetes patients
r a median follow-up of 9.5 years
HR total mortalityb HR CV mortalitya HR CV mortalityb
1 1 1
0.74 (0.59-0.93) 0.82 (0.57-1.17) 0.76 (0.52-1.10)
p=0.01 P=0.28 p=0.15
1 1
1.31 (1.01-1.70) 1.27 (0.87-1.72) 1.18 (0.80-1.78)
p =0.04 P=0.20 p=0.44
les (age, gender, diabetes duration, history of macrovascular complications,
rol-HDL ratio, and urinary albumin-to-creatinine ratio) according to model 2.
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glycemic control on mortality
Patients with two copies of the risk allele of rs2383206
(the GG-genotype) as compared to patients carrying the
non-risk allele (the AA and AG genotypes) had a signifi-
cantly greater risk of dying. The age and sex adjusted
HR was 1.31 (95%CI 1.03-1.65, p=0.03) for total mortal-
ity and 1.30 (95%CI 0.90-1.88, p=0.17) for cardiovascular
mortality. A significant interaction between rs2383206
and glycemic control in the analysis of total mortality
was detected in the Cox proportional hazard analyses
(for the genotypes: GG versus AA/AG, p=0.02). There
was no significant interaction between rs2383206 and
glycemic control in the analysis with cardiovascular mor-
tality (p=0.17) and therefore we only investigated the ef-
fect of the SNP with total mortality stratified according
to HbA1c tertiles. The age and sex adjusted relationship
between the rs2383206 genotypes and total mortality
was only significant in the lower two HbA1c tertiles
(HbA1c ≤6.7% and HbA1c 6.7% to 7.7%) (Table 3). For
model 1 the HR was 1.68 (95% CI 1.08-2.62, p=0.02),
1.48 (95%CI 1.01-2.19, p=0.04) and 0.92 (95% CI 0.60-
1.41, p=0.71) for the HbA1c categories HbA1c ≤6.7%,
HbA1c 6.7%-7.7% and >7.7%, respectively.
Discussion
This prospective study shows that three genetic risk va-
riants for T2D and CVD on 9p21 are associated with
total mortality in patients with T2D. We found that
being homozygous for the diabetes risk allele rs10811661
was protective for total mortality. We confirmed the pre-
viously reported association between two cardiovascular
risk alleles of the rs10757278 and rs2383206 variants
with an increased mortality risk. We also confirmed a
possible synergistic effect of glycemic control with the
‘CVD’ variant rs2383206 on mortality. However, this ef-
fect was present in the patients with good glycemic con-
trol, not in individuals with a poor glycemic control as
was shown previously [12].Table 3 Cox proportional hazard analysis for total
mortality by degree of glycemic control among type 2
diabetes patients according to the SNP rs2383206















AA/AG 674 (252) 1 1 1
GG 222 (96) 1.68 (1.08-2.62) 1.49 (1.01-2.19) 0.92 (0.60-1.41)
Missing 18 (10) p=0.02 p=0.04 p=0.71
a Corrected for age and sex.All three SNPs rs10811661, rs10757278 and rs2383206
are located in adjacent LD blocks of the 9p21 locus and
represent independent genetic markers for susceptibility
to T2D (rs10811661) and CVD (rs10757278 and
rs2383206, in high LD with each other (r2=0.86)) [16].
The closest genes in proximity of this region are
CDKN2A and CDKN2B, both of which are highly
expressed in pancreatic islet cells; CDKN2A plays a role
in pancreatic islet regenerative capacity [2]. To date, no
evidence of an association between the ‘T2D‘variant,
rs10811661, and CDKN2A and CDKN2B gene expression
in three relevant human tissues (i.e. the colon, liver and
pancreas) was found [18]. In contrast, the rs10757278
from the ‘CVD’ risk interval on 9p21 has been shown to
regulate cardiac CDKN2A/B expression [19]. Recently,
Harismendy et al. reported that the 9p21 locus is
enriched in enhancers including one that interacts with
the risk allele of rs10757278, emphasizing the important
role of rs10757278 [20]. The risk allele disrupts a binding
site for STAT1, the signal transducer for interferon-γ and
cytokines. And thus suggesting a direct mechanistic link
between the 9p21 region and atherosclerosis risk via al-
teration of vascular cell proliferation [19-21].
Association of the ‘T2D’9p21 variant with mortality
We found that having two ‘T2D‘risk T-alleles of the
rs10811661 variant was associated with a decreased total
mortality risk. One possible explanation of the observed
relationship between the genetic risk to T2D and lower
mortality could be that subjects who are genetically
prone to develop diabetes could develop this disease in
the relative absence of lifestyle related diabetes risk factors.
These lifestyle related factors, for example, increased ge-
neral and central adiposity are also associated with
chronic diseases and mortality [22,23]. Although our study
included only a limited number of patients with newly
diagnosed diabetes, there were no significant differences
in baseline variables, for example in BMI, between
patient’s homozygous vs. non-homozygous for the T2D
risk allele.
Another explanation could be that the observed rela-
tionship between the ‘T2D’ risk allele of rs10811661 and
low mortality in our study was in fact caused by its pro-
tective effect on other diseases. Interestingly, Beekman
et al. have recently found a positive relationship, al-
though non-significant, between the two ‘T2D’ risk
alleles of rs10811661 and longevity (OR 1.11 (95%CI
0.96-1.23)) [24], which is in agreement with our results.
This hypothesis may also be supported by recent studies
reporting an association between increased T2D genetic
susceptibility and reduced prostate cancer risk [25,26]. In
our study, we found no significant relationship with the
‘T2D’-risk allele and cancer mortality, although our sam-
ple size was probably too small to detect this association.
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causative mechanisms linking the genetic marker
rs10811661 with the pathophysiology of T2D were
revealed yet. Further studies are needed to confirm this
relationship and should also focus on the discovery of
potential molecular and physiological pathways explain-
ing T2D development.
Interaction between the ‘CVD’9p21 variant and glycemic
control on mortality
We observed an association between the homozygote
CVD-risk genotypes for rs10757278 and rs2383206 and
an increased risk of total mortality. Although there was
an increased risk for macrovascular complications at
baseline in patients with the ‘CVD’-risk genotype of
rs10757278, the association with the 9p21 variant and
cardiovascular mortality after follow-up was not signifi-
cant. The most likely explanation is that our study had a
lack of power to detect a difference in cardiovascular
mortality. Another explanation could be that in the
patients with T2D, the CVD-risk genotype influences the
initiation of atherosclerosis but not progression of athe-
rosclerosis [11].
In our study, the effect of the rs2383206 variant on
total mortality in diabetic patients was further influenced
by the degree of glycemic control. The effect of the risk
allele disappeared in individuals within the highest
HbA1c tertile. These results possibly suggest that for the
patients with low levels of HbA1c compared to the
patients with poor glycemic control, total mortality is
determined to a larger extent by genetic factors. Indeed,
in a previous ZODIAC study, we showed that HbA1c is
an important factor with regard to mortality risk, but
only in the patients with higher HbA1c level [27]. In
contrast with this, Doria et al. reported that cardiovascu-
lar and total mortality associated with the 9p21 variant
rs2383206 were higher in patients with poor glycemic
control [12]. Although we used the same statistical
model as Doria et al. [12], we could not confirm the sy-
nergism between rs2383206 and poor glycemic control
on mortality, neither did we observe an interaction be-
tween HbA1c level and rs2383206 with cardiovascular
mortality. The difference in these two observations can
be explained by various factors. First, HbA1c at baseline
was substantially lower in our cohort compared to the
HbA1c level in the prospective sample reported by Doria
et al. (7.3±1.1 versus 8.3±1.4, respectively) [12]. Se-
condly, the study by Doria et al. used multiple HbA1c
measurements before the study recruitment. Unfortu-
nately, these data were not available in the ZODIAC
study. Finally, it is possible that the strength of the asso-
ciation reported by Doria et al. may have been overesti-
mated due to selective forwarding of especially severe
CAD cases to the medical centers from which participantswere recruited in the above mentioned study. Thus, it
remains unclear to what extent differences between the
study populations, for example, in the baseline HbA1c level
or in the inclusion criteria, influenced the relationships be-
tween glycemic control and mortality in the carriers of two
risk alleles of rs2383206. Hence, additional replication stu-
dies are necessary to further investigate the interaction be-
tween the 9p21 locus and glycemic control.
Strengths and limitations
The unique strengths of our study include its prospect-
ive study design using a cohort of T2D patients with a
long follow-up for incident mortality, and the availability
of the baseline covariates to adjust for in the survival
analysis. Also, we selected three 9p21 genetic variants
based on the original GWA scans and the replication
studies in Europeans [5,6,8,12]. Recently a comprehen-
sive fine-mapping of the 9p21 region using the targeted
sequencing and the reference panel from 1000 Genome
project has been performed [28]. Although an additional
set of common associated variants was identified, no
stronger associations than the original GWAS signals
have been revealed.
It needs to be noted that the a priori selection process
of the SNPs could be the subject of debate. For example,
other ‘CVD’ associated variants in the 9p21 region such
as rs1333040 or 1333049 were also reported as inde-
pendently associated with cardiovascular disease [29].
However, rs1333040 and 1333049 are in high LD with
rs10757878 (r2=0.57 [6] and r2=0.93 [29] for rs1333040
and 1333049, respectively). Moreover, it has recently
been shown that the CVD risk allele of rs10757278 is
located in one of the enhancers and disrupts a binding
site for the transcription factor STAT1, thus, highlight-
ing the potential functional importance of rs10757278
[20]. Another limitation of our study is the number of
events that may have been insufficient to draw valid con-
clusions on cause specific mortality, i.e. cardiovascular
mortality. A third potential limitation concerns that only
the recessive genetic model was tested in our analysis.
To alleviate the multiple testing problems in the data by
reducing the number of statistical tests we have exclu-
sively performed our analysis according to the recessive
model as a predefined model. This model was selected a
priori and based on the reports from all previous pro-
spective studies [12,14,15,17], although we acknowledge
that some previous cross-sectional studies have also used
the additive model in their analyses [5].
Conclusion
In conclusion, our study provides evidence for associa-
tions between genetic variants on 9p21 with mortality in
T2D patients. We found that the genetic risk variant for
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risk variant for CVD increased the risk for mortality. We
also found that the effect of the ‘CVD’-risk variant on
mortality was further influenced by the degree of gly-
cemic control. Altogether, these observations indicate
heterogeneity in the association patterns between the
9p21 common variants and mortality and highlight the
central role of this genomic region on disease outcome
in T2D patients. Future studies should focus on investi-
gating the relationship between genetic and non-genetic
risk factors in the complex aetiology of T2D and its
complications.
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